Business Description
Jerusalem Pharmaceutical Co
ISIN : PS2016112695
Total Employee Number:
595Compare
Compare
Traded in other countries / regions
JPH.Palestine IPO Date
1997-01-20Description
Jerusalem Pharmaceutical Co is engaged in developing, manufacturing and marketing of human pharmaceuticals products. It also produces detergent, cosmetic, personal and home care products, veterinary and agricultural products. The company operates in Jordan, Algeria, the Middle East, and North Africa Region. Its product portfolio contains more than 300 pharmaceutical products in various dosage forms including tablets, capsules, sterile injectables, powders for suspensions, suspensions, syrups, powders, suppositories, ovules, creams, ointments, as well as ear and nose drops and solutions.
Financial Strength
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 5.06 | |||||
Equity-to-Asset | 0.76 | |||||
Debt-to-Equity | 0.03 | |||||
Debt-to-EBITDA | 0.15 | |||||
Interest Coverage | 46.16 | |||||
Piotroski F-Score | 6/9 | |||||
Altman Z-Score | 4.7 | |||||
Beneish M-Score | -1.7 | |||||
WACC vs ROIC | ||||||
Growth Rank
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 2 | |||||
3-Year EBITDA Growth Rate | 18.2 | |||||
3-Year EPS without NRI Growth Rate | 8.6 | |||||
3-Year FCF Growth Rate | -69.8 | |||||
3-Year Book Growth Rate | 10.7 |
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 13.53 | |||||
9-Day RSI | 26.27 | |||||
14-Day RSI | 34.51 | |||||
3-1 Month Momentum % | -8.27 | |||||
6-1 Month Momentum % | 59.13 | |||||
12-1 Month Momentum % | 80.74 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 3.31 | |||||
Quick Ratio | 2.62 | |||||
Cash Ratio | 0.59 | |||||
Days Inventory | 196.52 | |||||
Days Sales Outstanding | 261.8 | |||||
Days Payable | 118.38 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Dividend Yield % | 4.2 | |||||
Dividend Payout Ratio | 0.15 | |||||
3-Year Dividend Growth Rate | -12.6 | |||||
Forward Dividend Yield % | 4.2 | |||||
5-Year Yield-on-Cost % | 4.2 | |||||
Shareholder Yield % | 4.07 |
Profitability Rank
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | 57.86 | |||||
Operating Margin % | 27.32 | |||||
Net Margin % | 20.37 | |||||
EBITDA Margin % | 30.9 | |||||
FCF Margin % | -9.3 | |||||
OCF Margin % | -3.7 | |||||
ROE % | 12.51 | |||||
ROA % | 9.61 | |||||
ROIC % | 13 | |||||
3-Year ROIIC % | 4.07 | |||||
ROC (Joel Greenblatt) % | 20.81 | |||||
ROCE % | 14.89 | |||||
Years of Profitability over Past 10-Year | 10 |
GF Value Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PE Ratio | 12.53 | |||||
PE Ratio without NRI | 13.17 | |||||
Shiller PE Ratio | 17.45 | |||||
PEG Ratio | 0.59 | |||||
PS Ratio | 2.56 | |||||
PB Ratio | 1.44 | |||||
Price-to-Tangible-Book | 1.49 | |||||
EV-to-EBIT | 9.04 | |||||
EV-to-EBITDA | 7.76 | |||||
EV-to-Revenue | 2.4 | |||||
EV-to-FCF | -25.79 | |||||
Price-to-GF-Value | 1.48 | |||||
Price-to-Projected-FCF | 0.83 | |||||
Price-to-Median-PS-Value | 1.65 | |||||
Price-to-Peter-Lynch-Fair-Value | 0.82 | |||||
Price-to-Graham-Number | 0.93 | |||||
| Price-to-Net-Current-Asset-Value | 3.47 | |||||
Earnings Yield (Greenblatt) % | 11.06 | |||||
FCF Yield % | -3.63 | |||||
Forward Rate of Return (Yacktman) % | 22.01 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Jerusalem Pharmaceutical Co Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 50.191 | ||
| EPS (TTM) ($) | 0.285 | ||
| Beta | - | ||
| 3-Year Sharpe Ratio | 0.59 | ||
| 3-Year Sortino Ratio | 3.25 | ||
| Volatility % | 64.93 | ||
| 14-Day RSI | 34.51 | ||
| 14-Day ATR ($) | 0.031562 | ||
| 20-Day SMA ($) | 3.6965 | ||
| 12-1 Month Momentum % | 80.74 | ||
| 52-Week Range ($) | 1.9 - 4 | ||
| Shares Outstanding (Mil) | 36 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 6 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Jerusalem Pharmaceutical Co Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Jerusalem Pharmaceutical Co Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| USD 0.150000 Cash Dividend | 2026-04-16 | 3.05 (+3.57%) | ||
| 2:1 Stock Split | 2026-04-16 | 3.05 (+3.57%) | ||
| USD 0.040000 Cash Dividend | 2025-04-30 | 1.87 (+0.00%) |
Show
Entries
Jerusalem Pharmaceutical Co Frequently Asked Questions
What is Jerusalem Pharmaceutical Co(XPAE:JPH)'s stock price today?
The current price of XPAE:JPH is $3.57. The 52 week high of XPAE:JPH is $4.00 and 52 week low is $1.90.
When is next earnings date of Jerusalem Pharmaceutical Co(XPAE:JPH)?
The next earnings date of Jerusalem Pharmaceutical Co(XPAE:JPH) is .
Does Jerusalem Pharmaceutical Co(XPAE:JPH) pay dividends? If so, how much?
The Dividend Yield %  of Jerusalem Pharmaceutical Co(XPAE:JPH) is 4.2% (As of Today), Highest Dividend Payout Ratio of Jerusalem Pharmaceutical Co(XPAE:JPH) was 0.46. The lowest was 0.15. And the median was 0.3. The  Forward Dividend Yield % of Jerusalem Pharmaceutical Co(XPAE:JPH) is 4.2%. For more information regarding to dividend, please check our Dividend Page.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Articles on Jerusalem Pharmaceutical Co
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers